NASDAQ · Biotechnology

ACXP (ACXP) Stock

$1.40 -1.40% NASDAQ: ACXP Healthcare

Valuation

MetricValue
Price$1.40
Market Cap$2.22M
P/E Ratio-0.36
P/B Ratio0.60
P/S Ratio0.00
EPS (TTM)$-5.32
52-Week High$12.64
52-Week Low$1.33
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-160.00%
ROA-100.00%
ROCE-133.33%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio4.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-13.0M$-12.0M$-15.0M$-14.0M$-8.0M
Net Profit$-13.0M$-12.0M$-15.0M$-14.0M$-8.0M
EPS$-24.96$-22.36$-23.01$-17.59$-5.32
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$13.0M$9.0M$8.0M$4.0M$8.0M
Total Liabilities$1.0M$2.0M$3.0M$3.0M$2.0M
Cash$13.0M$9.0M$7.0M$4.0M$7.6B
Borrowings$0$0$0$0$0

Latest News

Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection PR Newswire · Jul 14, 2026 Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update PR Newswire · Jul 8, 2026 Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference PR Newswire · Jun 16, 2026 Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why Zacks · Jun 8, 2026 Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat ACCESS Newswire · May 19, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-5.0M$-8.0M$-10.0M$-10.0M$-6.8B
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$2.0M$0$10.6B
Net Cash Flow$10.0M$-4.0M$-2.0M$-4.0M$3.8B
Free Cash Flow$-5.0M$-8.0M$-10.0M$-10.0M$-6.8B

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-200.84%
Quick Ratio3.78
Interest Coverage—
Return 1Y-79.84%
Return 3Y-95.91%
Return 5Y-98.55%

Ownership

Insiders Held2.99%
Institutions Held6.17%
Institutions Float Held6.36%
Institutional HolderSharesReport Date
Jane Street Group, LLC54,6422026-03-31
Vanguard Capital Management LLC31,0992026-03-31
Geode Capital Management, LLC24,8192026-03-31
Cambridge Investment Research Advisors Inc.20,0002026-03-31
Vanguard Fiduciary Trust Co16,2052026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADIL $3.33 +1.22% -1.14 $3.20M 0.00%
APRE $0.62 -1.16% -0.47 $4.06M 0.00%
APVO $4.21 -4.10% -0.06 $9.21M 0.00%
BCDABioCardia, Inc. $0.84 -1.11% -0.83 $4.88M 0.00%
BCLIBrainstorm Cell Therapeutics Inc. $0.98 +6.52% -1.04 $10.81M 0.00%

About ACXP

ACXP is led by CEO David Luci, employs 4 people, headquartered in US, publicly traded since 2021.

ACXP stock trades at $1.40 with a market capitalization of $2.22M. The stock is valued at a price-to-earnings (P/E) ratio of -0.36, price-to-book of 0.60, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.33 and $12.64, and currently trades 88.9% below its 52-week high.

On profitability, ACXP generates a return on equity (ROE) of -160.00%, return on capital employed of -133.33%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides